The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.
The drug, called daraxonrasib, will be sold under the brand name Rasonque from Revolution Medicines. The daily pill targets multiple forms of a protein called RAS, which is a main driver of tumor growth.
A late-stage clinical trial with 500 patients showed that the median overall survival nearly doubled to more than 13 months versus a median survival of about 6.7 months for those being treated with standard chemotherapy.
“FDA approval of daraxonrasib is an exceptional moment for patients with pancreatic cancer and the culmination of many years of research to find a way to target KRAS,” Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, told ABC News in a statement.
“It brings a new treatment option and new hope to patients with metastatic pancreatic cancer, while giving us a foundation to make many more advances against this difficult disease,” the statement continued.
About 95% of exocrine pancreatic cancers in the U.S. are pancreatic adenocarcinoma, according to the American Cancer Society.
Although pancreatic adenocarcinoma represents only about 3.2% of all cancer diagnoses, it accounts for a disproportionately high share of cancer deaths, according to the FDA.
This is due to several factors including late detection, aggressive disease course and historically limited treatment options, the federal health agency said.
In June 2025, the FDA granted the drug a “Breakthrough Therapy” designation. This allows for expedited development and review of drugs that treat serious conditions and have preliminary evidence showing substantial improvement over available treatments.
The application was reviewed under the Commissioner’s National Priority Voucher Program, initiated by former FDA Commissioner Dr. Marty Makary. The review time was accelerated from 12 months to 10 months.
There is hope that this new type of targeted treatment will show benefits for other hard-to-treat cancers.
The FDA approval was granted for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or cancer treatments that target the entire body. Other drug candidates also include those getting multiagent systemic therapy, meaning two or more treatments.
Patients who participated in the clinical trial told “Good Morning America” in June that the drug renewed optimism about their prognoses.
One patient named Jim said that after beginning treatment with daraxonrasib, a tumor in his liver that had spread from his pancreas shrank significantly.
“The tumor that I had in my liver, which had spread from the pancreas, got reduced by 50%, which was incredible news,” he told “GMA.”
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
